Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Galli
Michele Moretti

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Cancers|October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet. Rheumatology|November 1, 2024
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases frameworkEmanuel Della-Torre, Rosaria Talarico, Jose Ballarin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Cancers|October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet. Rheumatology|November 1, 2024
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases frameworkEmanuel Della-Torre, Rosaria Talarico, Jose Ballarin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
Pageof 10